Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]
Balance (in shares) at Dec. 31, 2020			1,280,207
Unrealized loss on marketable securities	$ 0
Net loss	(8,421,892)		$ 0	$ 0		$ (8,421,892)
Balance (in shares) at Jun. 30, 2021			2,037,978
Balance at Dec. 31, 2020	24,814,182		$ 1,280	130,722,286		(105,909,384)
Sale of common stock and warrants, net of issuance costs (in shares)			673,171
Sale of common stock and warrants, net of issuance costs	31,094,302		$ 673	31,093,629		0
Issuance of common stock upon exercise of warrants (in shares)			84,600
Issuance of common stock upon exercise of warrants	2,201,450		$ 85	2,201,365		0
Stock-based compensation expense	478,560		0	478,560		0
Balance at Jun. 30, 2021	50,166,602		$ 2,038	164,495,840		(114,331,276)
Balance (in shares) at Mar. 31, 2021			2,037,978
Unrealized loss on marketable securities	0
Net loss	(3,777,973)		$ 0	0		(3,777,973)
Balance (in shares) at Jun. 30, 2021			2,037,978
Balance at Mar. 31, 2021	53,647,295		$ 2,038	164,198,560		(110,553,303)
Sale of common stock and warrants, net of issuance costs (in shares)			0
Sale of common stock and warrants, net of issuance costs	0		$ 0	0		0
Issuance of common stock upon exercise of warrants (in shares)			0
Issuance of common stock upon exercise of warrants	0		$ 0	0		0
Stock-based compensation expense	297,280		0	297,280		0
Balance at Jun. 30, 2021	50,166,602		$ 2,038	164,495,840		(114,331,276)
Balance (in shares) at Dec. 31, 2021		0	2,038,185
Balance at Dec. 31, 2021	34,911,467	$ 0	$ 2,038	164,914,540	$ 0	(130,005,111)
Conversion of Series C preferred stock to common stock (in shares)		(10,000)
Conversion of Series C preferred stock to common stock		$ (5,000)
Conversion of Series C preferred stock to common stock (in shares)			200
Stock-based compensation expense and vesting of restricted stock units (in shares)		0	529
Stock-based compensation expense and vesting of restricted stock units	556,261	$ 0	$ 0	556,261	0	0
Unrealized loss on marketable securities	(86,583)	0	0	0	(86,583)	0
Net loss	(8,717,142)	$ 0	$ 0	0	0	(8,717,142)
Balance (in shares) at Jun. 30, 2022		0	2,038,914
Balance at Jun. 30, 2022	26,669,003	$ 0	$ 2,038	165,475,801	(86,583)	(138,722,253)
Sale of Series C preferred stock to related parties (in shares)		10,000	0
Sale of Series C preferred stock to related parties	5,000	$ 5,000	$ 0	0	0	0
Balance (in shares) at Mar. 31, 2022		10,000	2,038,392
Balance at Mar. 31, 2022	30,618,299	$ 5,000	$ 2,038	165,192,671	(49,658)	(134,531,752)
Conversion of Series C preferred stock to common stock (in shares)		(10,000)
Conversion of Series C preferred stock to common stock		$ (5,000)
Conversion of Series C preferred stock to common stock (in shares)			200
Stock-based compensation expense and vesting of restricted stock units (in shares)		0	322
Stock-based compensation expense and vesting of restricted stock units	278,130	$ 0	$ 0	278,130	0	0
Unrealized loss on marketable securities	(36,925)	0	0	0	(36,925)	0
Net loss	(4,190,501)	$ 0	$ 0	0	0	(4,190,501)
Balance (in shares) at Jun. 30, 2022		0	2,038,914
Balance at Jun. 30, 2022	$ 26,669,003	$ 0	$ 2,038	165,475,801	$ (86,583)	$ (138,722,253)
Conversion of Series C preferred stock to common stock				$ 5,000